Safety, Tolerability and Efficacy of Adjunctive TBO-309 in Reperfusion for Stroke With Tandem Occlusion

NCT06813651 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

78

Enrollment

INDUSTRY

Sponsor class

Conditions

Ischemic Stroke
Tandem Occlusion

Interventions

DRUG: TBO-309: 60 mg
DRUG: TBO-309: 120 mg
DRUG: TBO-309: 30 mg

Sponsor

ThromBio Pty. Ltd.